Investing Profile

David Grayzel

Photo of David Grayzel, Partner at Atlas Venture

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
$500K - $5.0M
$2.0M
13
CompanyStageDateRound SizeTotal Raised
Vima Therapeutics
Series AMar 2026$40M
Series AMay 2025$60M
$100M
Triana Biomedicines
Series BDec 2025$120M
Series AApr 2022$110M
$230M
Co-investors: Andrew Hedin (Bessemer Venture Partners)
Affinia Therapeutics
Series COct 2025$40M
Series BMay 2021$110M
Series AMar 2020$60M
$210M
Co-investors: Ed Mathers (New Enterprise Associates (NEA))
Trace Neuroscience
Series ANov 2024$100M
$100M
Co-investors: Anthony Philippakis (GV (Google Ventures)), Jeffrey Tong (Third Rock Ventures)
Q32 Bio
Post Ipo EquityMar 2024$42M
Series BOct 2020$60M
Series AMay 2020$46M
$150M
Comanche Biopharma
Series BJan 2024$75M
$110M
Co-investors: Brendan Bulik-Sullivan (GV (Google Ventures)), Scott Gottlieb (New Enterprise Associates (NEA))
Delinia
Series ASep 2016$35M
$35M